Management of Metastatic Rectal Cancer with Disease Progression

Assessment and Management

The European Society for Medical Oncology recommends discontinuing radiation therapy and initiating combination chemotherapy with FOLFOX or FOLFIRI plus a targeted agent for patients with metastatic rectal cancer showing disease progression during radiation therapy 1, 2
Patients with metastatic colorectal cancer should be evaluated for disease progression using tumor markers and imaging studies, such as CT scans or MRI, to assess the extent of disease progression and identify potential metastatic sites 1, 2
The National Comprehensive Cancer Network recommends re-evaluating patients after 2-3 cycles of chemotherapy to assess response and adjust therapy accordingly 2, 3, 5
Combination chemotherapy provides higher response rates, longer progression-free survival, and better overall survival than single-agent therapy for patients with metastatic colorectal cancer, according to the European Society for Medical Oncology 1, 2
The American Society of Clinical Oncology recommends considering surgical or radiation options if a major partial response is achieved in previously unresectable disease 2, 3

The European Society for Medical Oncology recommends using FOLFOX (5-FU/leucovorin/oxaliplatin) or FOLFIRI (5-FU/leucovorin/irinotecan) as first-line therapy for patients with metastatic colorectal cancer, with the addition of a targeted biological agent based on molecular testing 1, 2, 3
Patients with significant weight loss, such as 7 pounds, should be considered for immediate intervention, as this is a significant clinical indicator of disease progression, according to the European Society for Medical Oncology 3

Patients should be monitored for response to chemotherapy and adjusted accordingly, with consideration of surgical or radiation options if a major partial response is achieved, as recommended by the National Comprehensive Cancer Network 2, 3, 5